Abstract: A data transmission method includes: displaying a target message in a session interface; in response to a trigger operation on the target message, outputting a resource transmission interface including an object display region and an icon display region; and the object display region including an object identifier of at least one transmission object, and the icon display region including a message icon corresponding to the target message; moving the message icon from the icon display region to the object display region according to a moving operation on the message icon; and transmitting, in response to the message icon being moved to the object display region, the data resource to a target transmission object of the at least one transmission object in the object display region, the target transmission object being determined according to an ending position of a movement track of the message icon corresponding to the moving operation.

Abstract: An acceleration unit including a primary core and a secondary core is provided. The primary core includes a first on-chip memory, a primary core sequencer adapted to decode a received first cross-core copy instruction, and a primary core memory copy engine adapted to acquire a first operand from a first address in the first on-chip memory and copy the acquired first operand to a second address in a second on-chip memory of the secondary core. Further, the secondary core includes a second on-chip memory, a secondary core sequencer adapted to decode a received second cross-core copy instruction, and a secondary core memory copy engine adapted to acquire the first operand from the second address in the second on-chip memory and copy the acquired first operand back to the first address in the first on-chip memory.

Abstract: An acceleration unit including a primary core and a secondary core. The primary core includes: a first on-chip memory; a primary core sequencer adapted to decode a received first cross-core copy instruction; and a primary core memory copy engine adapted to acquire a first operand from a first address in the first on-chip memory and copy the acquired first operand to a second address in a second on-chip memory of the secondary core. The secondary core includes: a second on-chip memory; a secondary core sequencer adapted to decode a received second cross-core copy instruction; and a secondary core memory copy engine adapted to acquire the first operand from the second address in the second on-chip memory and copy the acquired first operand back to the first address in the first on-chip memory.

Abstract: Disclosed are amide compounds, preparation method and uses thereof, specifically, the compounds represented by formula I or pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, Q, X and n are defined as in the description. Also disclosed are a method for preparing the compounds of formula I, a composition containing the compounds, and the uses of the same in the preparation of medicaments for regulating blood lipid and/or preventing gallstone. The compounds of formula I disclosed in the present invention have stability in vitro, good solubility in the pharmaceutical organic solvents and favorable bioavailability in animals.

Abstract: In general, the invention is directed to techniques for scheduling resource access within an intermediate network device. For example, as described herein, a device receives packets for a plurality of sessions that include application-layer data for the sessions. The device determines a weight for each of the plurality of sessions and, during periods of resource congestion, selects one or more sessions for additional resource allocation based on the respective weights of the sessions. The device allocates additional memory resources to selected sessions to enable further buffering of application-layer data such that the device may apply the service to multiple sessions concurrently despite the resource congestion.

Abstract: An amorphous asiatic tromethamine salt and the preparation method thereof. The method includes the steps of: (1) dissolving asiatic acid in an organic solvent; step (2) mixing with tromethamine; step (3) stirring and salifying the same, and then removing the organic solvent. The method for preparing the amorphous asiatic tromethamine salt is easy and effective, and the water solubility and bioavailability of the asiatic tromethamine salt thus obtained are greatly compared with the prior art.

Abstract: An amorphous asiatic tromethamine salt and the preparation method thereof. The method includes the steps of: (1) dissolving asiatic acid in an organic solvent; step (2) mixing with tromethamine; step (3) stirring and salifying the same, and then removing the organic solvent. The method for preparing the amorphous asiatic tromethamine salt is easy and effective, and the water solubility and bioavailability of the asiatic tromethamine salt thus obtained are greatly compared with the prior art.

Abstract: Disclosed are amide compounds, preparation method and uses thereof, specifically, the compounds represented by formula I or pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, Q, X and n are defined as in the description. Also disclosed are a method for preparing the compounds of formula I, a composition containing the compounds, and the uses of the same in the preparation of medicaments for regulating blood lipid and/or preventing gallstone. The compounds of formula I disclosed in the present invention have stability in vitro, good solubility in the pharmaceutical organic solvents and favorable bioavailability in animals.

Abstract: The invention discloses a dithiolopyrrolone compound represented by formula I or its pharmaceutically acceptable salts, wherein X1, R1, R2, R3, R4 are defined as in the description. The invention also discloses the preparation of such compounds, and the use of such compounds in preparation of medicaments for increasing peripheral white blood cells and in preparation of ancillary medicaments for inhibiting the decrease of peripheral white blood cells in radiotherapy or chemotherapy.

Abstract: A method includes receiving a data unit, determining whether a current state, associated with a deterministic finite automata (DFA) that includes a portion of states in a bitmap and a remaining portion of states in a DFA table, is a bitmap state or not, and determining whether a value corresponding to the data unit is greater than a threshold value, when it is determined that the current state is not a bitmap state. The method further includes determining whether the current state is insensitive, when it is determined that the value corresponding to the data unit is greater than the threshold value, where insensitive means that each next state is a same state for the current state, and selecting a default state, as a next state for the current, when it is determined that the current state is insensitive.

Abstract: A method includes receiving a data unit, determining whether a current state, associated with a deterministic finite automata (DFA) that includes a portion of states in a bitmap and a remaining portion of states in a DFA table, is a bitmap state or not, and determining whether a value corresponding to the data unit is greater than a threshold value, when it is determined that the current state is not a bitmap state. The method further includes determining whether the current state is insensitive, when it is determined that the value corresponding to the data unit is greater than the threshold value, where insensitive means that each next state is a same state for the current state, and selecting a default state, as a next state for the current, when it is determined that the current state is insensitive.

Abstract: The invention discloses a dithiolopyrrolone compound represented by formula I or its pharmaceutically acceptable salts, wherein X1, R1, R2, R3, R4 are defined as in the description. The invention also discloses the preparation of such compounds, and the use of such compounds in preparation of medicaments for increasing peripheral white blood cells and in preparation of ancillary medicaments for inhibiting the decrease of peripheral white blood cells in radiotherapy or chemotherapy.

Abstract: Sugar-modified SIN-1 compositions are provided. The compositions are useful for generating NO in response to hydrolytic activity of a glycosidase specific for the O-glycosidic bond between the sugar and SIN-1 moieties. Pharmaceutical compositions containing the sugar-modified SIN-1 compositions and methods of using the compositions are also provided.

Abstract: Sugar-modified SIN-1 compositions are provided. The compositions are useful for generating NO in response to hydrolytic activity of a glycosidase specific for the O-glycosidic bond between the sugar and SIN-1 moieties. Pharmaceutical compositions containing the sugar-modified SIN-1 compositions and methods of using the compositions are also provided.